Listen on the go
CORRECT!
Next question
touchHAEMATOLOGY touchHAEMATOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Haematological Malignancies

    EU Partner

    An Introduction to Haematological Malignancies

    In recent years, advances in our understanding of the pathological mechanisms underlying haematological malignancies have led to improved outcomes. Several novel drug classes are now emerging, including chimeric antigen receptor (CAR) T-cell therapy, molecular targeted therapies, bispecific T-cell engaging antibodies, CD47 blockade therapy and antibody-drug conjugates. Many challenges remain, however, including how best to combine agents and determining where new therapies fit into the treatment paradigm.

    Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.”

    Our supporting partners do not constitute an endorsement of the content on this page.

    Haematological Malignancies Content

    Haematological Malignancies, Myelodysplastic Syndrome
    Advancing care in myelodysplastic syndromes: Expert insights from Prof. Pierre Fenaux

    Prof. Pierre Fenaux, Head of the Department of  Hematology and Immunology at Assistance Publique-Hôpitaux de Paris Nord (Hôpitaux Saint-Louis, R Debré, Avicenne) is a leading expert in haematology with extensive experience in the treatment and management of myelodysplastic syndromes (MDS). In this interview, he discusses key considerations for first-line therapies in lower-risk MDS, the latest advances in treatment and the role of organizations like the European School of Hematology (ESH) in supporting haematologists.

    Leukaemia, Haematological Malignancies
    Watch Time: 50 mins
    touchCONGRESS
    Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024
    Prof. Gianantonio Rosti, Dr Carla Boquimpani, Prof. Dr. med. Susanne Saussele Translations available:

    Watch this touchCONGRESS activity exploring advances in treatments for patients with CML, based on data from 2024 congresses, including EHA and ESH-iCMLf.

    Learning objectives
    Learning Objectives
    • Evaluate the latest data for approved and emerging tyrosine kinase inhibitors for chronic myeloid leukaemia in the first-line setting
    • Discuss the data for approved and emerging tyrosine kinase inhibitors for chronic myeloid leukaemia in the second- and later-line settings
    • Summarize the potential impact of emerging findings from clinical trials and real-world studies on current and future clinical practice in chronic myeloid leukaemia
    Leukaemia, Haematological Malignancies, Lymphoma
    Space medicine: Can microgravity transform pharmaceutical manufacturing?

    In our latest episode, we delve into the world of space medicine to explore how drug crystallization in microgravity could revolutionize biologic drug administration. Joining us is Dr Katie King, CEO of BioOrbit, to discuss the science, challenges, and technological advancements that could make space-based drug production a reality.

    Haematological Malignancies
    New study offers hope for motherhood after allogeneic stem cell transplantation

    A new study published in Blood explores the potential for successful pregnancy after allogeneic stem cell transplantation (allo-SCT), providing new hope for women who have undergone this intense treatment.

    Haematological Malignancies, Lymphoma
    Watch Time: 39 mins
    touchPANEL DISCUSSION
    Maximizing the possibilities in the evolving treatment paradigm for R/R follicular lymphoma: From optimal sequencing to shared decision-making
    CE/CME ACCREDITED Dr Matthew Lunning, Professor Charalambos Andreadis, Dr Tara Graff Translations available:

    Haematology experts discuss the latest on novel therapies and treatment selection and sequencing in R/R FL

    Leukaemia, Haematological Malignancies
    Blood multiple myeloma
    Olutasidenib offers hope in AML for patients with IDH1 mutations

    A recent review by Prof. Florence Pasquier and colleagues highlights the potential of olutasidenib, a selective, oral, small-molecule inhibitor of the mutant IDH1 enzyme, recently approved  by the FDA as treatment option for patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with isocitrate dehydrogenase 1 (IDH1) mutations.

    Haematological Malignancies
    Supporting young haematologists: Insights on YoungEHA and EHA 24
    Mandy Lauw Watch Time: 10 mins

    Dr. Mandy Lauw, outgoing Chair of the YoungEHA Committee, discusses how YoungEHA supports young hematology professionals and offers tips on maximizing the EHA Congress for career development. Topics covered include the main aim and mission of YoungEHA, YoungEHA's contributions to this year’s EHA Congress and throughout the year, how young professionals can get the most out of the EHA Congress and its available activities and resources, making the most of virtual attendance, the main aims of the YoungEHA committee for the coming year and Dr. Lauw's hopes for the committee's future.

    Haematological Malignancies, Paediatric Haematology
    Watch Time: 52 mins
    touchPANEL DISCUSSION
    Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management
    CE/CME ACCREDITED Prof. Dr Vito Sabato, Dr Sigurd Broesby-Olsen, Prof. Prithviraj Bose Translations available:

    Multidisciplinary experts discuss the diagnosis and management of patients with systemic mastocytosis.

    Learning objectives
    Learning Objectives
    • Describe the signs, symptoms and diagnostic pathway for systemic mastocytosis
    • Explain how to apply personalized treatment strategies using a multidisciplinary approach to effectively manage systemic mastocytosis
    • Recall the latest data for new and emerging treatments for systemic mastocytosis and evaluate their potential impact on the clinical management of systemic mastocytosis in the future
    Paediatric Haematology, Haematological Malignancies, Genetic Blood Disorders
    Watch Time: 48 mins
    touchMDT
    Recognizing and managing HLH in the critical care setting: Best practice for the multidisciplinary team
    CE/CME ACCREDITED Prof. Michael Jordan, Dr Kate Kernan, Dr Eric Gars, Prof. Rob MacLaren Translations available:

    Multidisciplinary experts discuss the diagnosis and management of haemophagocytic lymphohistiocytosis (HLH)

    Learning objectives
    Learning Objectives
    • Describe the characteristic clinical and laboratory findings of HLH, and the confirmatory diagnostic tests
    • Explain the identification of predisposing conditions and acute triggers associated with HLH and how these affect treatment selection and monitoring
    • Implement effective multidisciplinary strategies for the diagnosis, monitoring and management of HLH in the critical care setting
    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchHAEMATOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup